<DOC>
	<DOCNO>NCT02964949</DOCNO>
	<brief_summary>Atrial fibrillation heart 's two upper chamber ( call atrium ) beat chaotically irregularly , coordination two low chamber ( call ventricle ) heart . This lead blood clot form heart chamber . Patients atrial fibrillation treat either 60 mg 75 mg edoxaban 12 month , 2-4 week follow-up , participation complete . Blood sample collect first dose study drug ( Day 0 ) , Days 30 , 90 360 ( pre dose , 1-2 hour post dose 4-8 hour post-dose ) .</brief_summary>
	<brief_title>Comparison Two Doses Edoxaban Using Different Tests ( Assays ) Clinical Outcomes</brief_title>
	<detailed_description />
	<mesh_term>Atrial Fibrillation</mesh_term>
	<mesh_term>Edoxaban</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<criteria>Meets protocolspecified criterion qualification Is able follow protocol specify contraception method Is willing able comply restriction relate food , drink medication Voluntarily consent participate provide write informed consent prior protocolspecific procedure Has history current use overthecounter medication , dietary supplement , drug ( include nicotine alcohol ) outside protocolspecified parameter Has sign , symptom history condition , per protocol opinion investigator , might compromise : 1. safety wellbeing participant study staff 2. safety wellbeing participant 's offspring ( pregnancy breastfeed ) 3. analysis result</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Nonvalvular Atrial Fibrillation</keyword>
	<keyword>High Creatinine Clearance</keyword>
	<keyword>Developmental Phase III</keyword>
	<keyword>Anticoagulant Na√Øve</keyword>
</DOC>